Status:
RECRUITING
Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers
Lead Sponsor:
Queen Mary University of London
Collaborating Sponsors:
University of Liverpool
University College, London
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Urine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of diagnosing diseases of t...
Detailed Description
The main aim of this research study is to establish the accuracy of a urinary biomarker panel (LYVE1, REG1B, TFF1), and affiliated PancRISK score alone or in combination with plasma CA19-9 for early d...
Eligibility Criteria
Inclusion
- Inclusion criteria (Symptomatic patients):
- Able and willing to give informed consent
- ≥18 years old
- Suspected pancreatic diseases with symptoms including, but not limited to, diarrhoea, back pain, abdominal pain, nausea, vomiting, constipation or new onset diabetes
- Exclusion criteria (Symptomatic patients):
- Current or prior treatment (chemotherapy, radiotherapy, surgical resection, biological therapy, and immunotherapy) for any malignancy other than basal cell carcinoma within 5 years of enrolment.
- Asymptomatic participants will be identified through the EUROPAC registry and will fulfil EUROPAC's eligibility criteria.
Exclusion
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT04449406
Start Date
January 1 2020
End Date
August 31 2026
Last Update
January 7 2026
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
EUROPAC study, University of Liverpool
Liverpool, United Kingdom
2
ADEPTS study, University College London
London, United Kingdom
3
Imperial College London
London, United Kingdom
4
Royal London Hospital
London, United Kingdom